| Compound Information | SONAR Target prediction |
| Name: | TRANEXAMIC ACID |
| Unique Identifier: | SPE01502026 |
| MolClass: | Checkout models in ver1.5 and ver1.0 |
| Molecular Formula: | |
| Molecular Weight: | 142.091 g/mol |
| X log p: | -1.294 (online calculus) |
| Lipinksi Failures | 0 |
| TPSA | 17.07 |
| Hydrogen Bond Donor Count: | 0 |
| Hydrogen Bond Acceptors Count: | 3 |
| Rotatable Bond Count: | 2 |
| Canonical Smiles: | NCC1CCC(CC1)C(O)=O |
| Source: | synthetic |
| Therapeutics: | hemostatic |
| Generic_name: | Tranexamic Acid |
| Chemical_iupac_name: | 4-(aminomethyl)cyclohexane-1-carboxylic acid |
| Drug_type: | Approved Drug |
| Pharmgkb_id: | PA451738 |
| Kegg_compound_id: | D01136 |
| Drugbank_id: | APRD01270 |
| Melting_point: | >300 oC |
| H2o_solubility: | 1.67E+005 mg/L |
| Logp: | 0.66 |
| Cas_registry_number: | 1197-18-8 |
| Drug_category: | Antifibrinolytic Agents; ATC:B02AA02 |
| Indication: | For use in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. |
| Pharmacology: | Tranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. Tranexamic acid is a competitive inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. Tranexamic acid is about 10 times more potent in vitro than aminocaproic acid. Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. Tranexamic acid in a concentration of 1 mg per mL does not aggregate platelets in vitro. In patients with hereditary angioedema, inhibition of the formation and activity of plasmin by tranexamic acid may prevent attacks of angioedema by decreasing plasmin-induced activation of the first complement protein (C1). |
| Mechanism_of_action: | Tranexamic acid competitively inhibits activation of plasminogen (via binding to the kringle domain), thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots, fibrinogen, and other plasma proteins, including the procoagulant factors V and VIII. Tranexamic acid also directly inhibits plasmin activity, but higher doses are required than are needed to reduce plasmin formation. |
| Organisms_affected: | Humans and other mammals |
| Found: 205 nonactive as graph: single | with analogs | [1] << Back 1 2 3 4 5 6 7 8 9 10 Next >> [205] |
| Species: | 4932 |
| Condition: | ATP4 |
| Replicates: | 2 |
| Raw OD Value: r im | 0.6569±0.00127279 |
| Normalized OD Score: sc h | 0.9931±0.00571028 |
| Z-Score: | -0.2677±0.233429 |
| p-Value: | 0.791726 |
| Z-Factor: | -14.9033 |
| Fitness Defect: | 0.2335 |
| Bioactivity Statement: | Nonactive |
| ps |
| DBLink | Rows returned: 95 | << Back 11 12 13 14 15 16 Next >> |
| 7431966 | (6S)-6-aminotetradecanedioic acid |
| 7431967 | (6R)-6-azaniumyltetradecanedioate |
| 7431968 | (6R)-6-aminotetradecanedioic acid |
| 7431976 | (3S)-10-azaniumyl-3-methyl-decanoate |
| 7431977 | (3S)-10-amino-3-methyl-decanoic acid |
| 7431978 | (3R)-10-azaniumyl-3-methyl-decanoate |
| internal high similarity DBLink | Rows returned: 7 | 1 2 Next >> |
| JFD 01160 | 0.9286 |
| LOPAC 00333 | 0.9286 |
| LOPAC 00590 | 0.9286 |
| RJC 00670 | 0.9286 |
| SB 02002 | 0.9286 |
| LOPAC 00685 | 0.9615 |
| active | Cluster 4207 | Additional Members: 3 | Rows returned: 0 |
Service provided by the
Mike Tyers Laboratory